ACE2 correlates with immune infiltrates in colon adenocarcinoma: Implication for COVID-19

Ahmadi, Mohsen; Pashangzadeh, Salar; Mousavi, Pegah; Saffarzadeh, Negin; Habibi, Mohammad Amin; Hajiesmaeili, Fatemeh; Rezaei, Nima

doi:10.1016/j.intimp.2021.107568

Cited by 10 publications

(8 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of BP were enriched in humoral immune-related pathways and Signal recognition particle (SRP)-associated proteins. The results of Ahmadi et al also suggest a strong relationship between colon adenocarcinoma and immunity [ 30 ]. CC processes focused nucleosome, DNA complexes and other processes that are closely related to tumor cell growth and proliferation [ 31 , 32 ].…”

Section: Resultsmentioning

confidence: 99%

In Silico Identification and Validation of Cuproptosis-Related LncRNA Signature as a Novel Prognostic Model and Immune Function Analysis in Colon Adenocarcinoma

et al. 2022

View full text Add to dashboard Cite

Background: Colon adenocarcinoma (COAD) is the most common subtype of colon cancer, and cuproptosis is a recently newly defined form of cell death that plays an important role in the development of several malignant cancers. However, studies of cuproptosis-related lncRNAs (CRLs) involved in regulating colon adenocarcinoma are limited. The purpose of this study is to develop a new prognostic CRLs signature of colon adenocarcinoma and explore its underlying biological mechanism. Methods: In this study, we downloaded RNA-seq profiles, clinical data and tumor mutational burden (TMB) data from the TCGA database, identified cuproptosis-associated lncRNAs using univariate Cox, lasso regression analysis and multivariate Cox analysis, and constructed a prognostic model with risk score based on these lncRNAs. COAD patients were divided into high- and low-risk subgroups based on the risk score. Cox regression was also used to test whether they were independent prognostic factors. The accuracy of this prognostic model was further validated by receiver operating characteristic curve (ROC), C-index and Nomogram. In addition, the lncRNA/miRNA/mRNA competing endogenous RNA (ceRNA) network and protein–protein interaction (PPI) network were constructed based on the weighted gene co-expression network analysis (WGCNA). Results: We constructed a prognostic model based on 15 cuproptosis-associated lncRNAs. The validation results showed that the risk score of the model (HR = 1.003, 95% CI = 1.001–1.004; p < 0.001) could serve as an independent prognostic factor with accurate and credible predictive power. The risk score had the highest AUC (0.793) among various factors such as risk score, stage, gender and age, also indicating that the model we constructed to predict patient survival was better than other clinical characteristics. Meanwhile, the possible biological mechanisms of colon adenocarcinoma were explored based on the lncRNA/miRNA/mRNA ceRNA network and PPI network constructed by WGCNA. Conclusion: The prognostic model based on 15 cuproptosis-related lncRNAs has accurate and reliable predictive power to effectively predict clinical outcomes in colon adenocarcinoma patients.

show abstract

Section: Resultsmentioning

confidence: 99%

In Silico Identification and Validation of Cuproptosis-Related LncRNA Signature as a Novel Prognostic Model and Immune Function Analysis in Colon Adenocarcinoma

et al. 2022

View full text Add to dashboard Cite

show abstract

“…By collecting and collating examination reports from COVID-19 positive patients, Karla et al found that cancer patients were 1.6 times more at risk of being infected by SARS-CoV-2 than healthy people, while cancer patients undergoing chemotherapy or immunotherapy were at an even higher risk of infection, approximately 2.2 times ( Lee et al, 2021 ). In addition, SARS-CoV-2 virus contributes to the poor prognosis of COAD patients by affecting the process of immune cell infiltration ( Ahmadi et al, 2021 ). Therefore, there is an urgent need to explore drugs for the treatment of COAD/COVID-19.…”

Section: Introductionmentioning

confidence: 99%

Potential therapeutic strategies for quercetin targeting critical pathological mechanisms associated with colon adenocarcinoma and COVID-19

Liang²,

Yu³

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Patients with colon adenocarcinoma (COAD) are at a higher probability of infection with COVID-19 than healthy individuals. However, there is no globally accepted treatment protocol for patients with COAD/COVID-19. Quercetin has been found to have significant antitumor, antiviral and anti-inflammatory effects in several studies. Therefore, this study sought to evaluate the potential of quercetin as the agent for COAD/COVID-19 and to explore its mechanisms. We used bioinformatics algorithms to obtain COAD/COVID-19-related genes (CCRG) from COAD-related transcriptome data and COVID-related transcriptome sequencing data, and used these genes to construct a COAD prognostic model. We intersected the CCRG with the therapeutic target genes of quercetin and obtained a total of 105 genes (potential target genes of quercetin for the treatment of COAD/COVID-19). By constructing a protein-protein interaction (PPI) network, we ascertained FOS, NFKB1, NFKB1A, JUNB, and JUN as possible core target genes of quercetin for the treatment of COAD/COVID-19. Bioinformatic analysis of these 105 genes revealed that the mechanisms for quercetin the treatment of COAD/COVID-19 may be associated with oxidative stress, apoptosis, anti-inflammatory, immune, anti-viral and multiple pathways containing IL-17, TNF, HIF-1. In this study, we constructed a prognostic model of COAD/COVID19 patients by using CCRG and elucidated for the first time the potential target genes and molecular mechanisms of quercetin for the treatment of COAD/COVID-19, which may benefit the clinical treatment of COAD/COVID-19 patients. However, no clinical trials have yet been conducted to further validate the findings, but this will be the future direction of our research.

show abstract

“…A systematic review of 52 pooled studies showed that patients with cancer and infected with COVID-19 exhibited a higher death risk (3). Similarly, Ahmadi's group showed that COVID-19 brings unfavorable survival outcomes for patients with colon cancer via the alteration of the immune cell infiltration-linked process (4), and the COVID-19 pandemic led to widespread disruption of colorectal cancer services (5). So, there is a need to identify alternative therapeutic compounds to reduce the severity and mortality rate of COVID-19 in patients with cancer.…”

Section: Introductionmentioning

confidence: 99%

Therapeutic targets and functions of curcumol against COVID-19 and colon adenocarcinoma

Peng

Lai

2022

Front. Nutr.

View full text Add to dashboard Cite

Since 2019, the coronavirus disease (COVID-19) has caused 6,319,395 deaths worldwide. Although the COVID-19 vaccine is currently available, the latest variant of the virus, Omicron, spreads more easily than earlier strains, and its mortality rate is still high in patients with chronic diseases, especially cancer patients. So, identifying a novel compound for COVID-19 treatment could help reduce the lethal rate of the viral infection in patients with cancer. This study applied network pharmacology and systematic bioinformatics analysis to determine the possible use of curcumol for treating colon adenocarcinoma (COAD) in patients infected with COVID-19. Our results showed that COVID-19 and COAD in patients shared a cluster of genes commonly deregulated by curcumol. The clinical pathological analyses demonstrated that the expression of gamma-aminobutyric acid receptor subunit delta (GABRD) was associated with the patients' hazard ratio. More importantly, the high expression of GABRD was associated with poor survival rates and the late stages of COAD in patients. The network pharmacology result identified seven-core targets, including solute carrier family 6 member 3, gamma-aminobutyric acid receptor subunit pi, butyrylcholinesterase, cytochrome P450 3A4, 17-beta-hydroxysteroid dehydrogenase type 2, progesterone receptor, and GABRD of curcumol for treating patients with COVID-19 and COAD. The bioinformatic analysis further highlighted their importance in the biological processes and molecular functions in gland development, inflammation, retinol, and steroid metabolism. The findings of this study suggest that curcumol could be an alternative compound for treating patients with COVID-19 and COAD.

show abstract

ACE2 correlates with immune infiltrates in colon adenocarcinoma: Implication for COVID-19

Cited by 10 publications

References 65 publications

In Silico Identification and Validation of Cuproptosis-Related LncRNA Signature as a Novel Prognostic Model and Immune Function Analysis in Colon Adenocarcinoma

In Silico Identification and Validation of Cuproptosis-Related LncRNA Signature as a Novel Prognostic Model and Immune Function Analysis in Colon Adenocarcinoma

Potential therapeutic strategies for quercetin targeting critical pathological mechanisms associated with colon adenocarcinoma and COVID-19

Therapeutic targets and functions of curcumol against COVID-19 and colon adenocarcinoma

Contact Info

Product

Resources

About